Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free AVTE Stock Alerts

Aerovate Therapeutics (AVTE) Competitors

Aerovate Therapeutics logo
$24.52 +0.29 (+1.20%)
As of 05/4/2026
Compare

AVTE vs. BEAM, GMTX, DYN, ARQT, and MOR

Should you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Beam Therapeutics (BEAM), Gemini Therapeutics (GMTX), Dyne Therapeutics (DYN), Arcutis Biotherapeutics (ARQT), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.

How does Aerovate Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

99.7% of Beam Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Beam Therapeutics presently has a consensus target price of $49.36, suggesting a potential upside of 70.79%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Beam Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.75
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Aerovate Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -57.24%. Beam Therapeutics' return on equity of -30.65% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-57.24% -30.65% -23.73%
Aerovate Therapeutics N/A -90.19%-77.47%

In the previous week, Beam Therapeutics had 5 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 6 mentions for Beam Therapeutics and 1 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.75 beat Beam Therapeutics' score of 0.65 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aerovate Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Beam Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Aerovate Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$139.74M21.25-$79.99M-$1.01N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

Summary

Beam Therapeutics beats Aerovate Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Gemini Therapeutics' return on equity of -38.78% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gemini TherapeuticsN/A -38.78% -35.88%
Aerovate Therapeutics N/A -90.19%-77.47%

In the previous week, Gemini Therapeutics and Gemini Therapeutics both had 1 articles in the media. Aerovate Therapeutics' average media sentiment score of 0.75 beat Gemini Therapeutics' score of 0.00 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gemini Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aerovate Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/A-$71.87M-$1.00N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

Summary

Gemini Therapeutics beats Aerovate Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/A-$446.21M-$3.54N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

96.7% of Dyne Therapeutics shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Dyne Therapeutics' return on equity of -61.46% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dyne TherapeuticsN/A -61.46% -50.94%
Aerovate Therapeutics N/A -90.19%-77.47%

In the previous week, Dyne Therapeutics had 5 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 6 mentions for Dyne Therapeutics and 1 mentions for Aerovate Therapeutics. Dyne Therapeutics' average media sentiment score of 0.95 beat Aerovate Therapeutics' score of 0.75 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyne Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aerovate Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Dyne Therapeutics presently has a consensus target price of $35.14, suggesting a potential upside of 101.16%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Dyne Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyne Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
3 Strong Buy rating(s)
2.94
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Dyne Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Summary

Dyne Therapeutics beats Aerovate Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Arcutis Biotherapeutics has higher revenue and earnings than Aerovate Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis Biotherapeutics$376.07M7.79-$16.14M-$0.14N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

Aerovate Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -4.29%. Arcutis Biotherapeutics' return on equity of -10.26% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcutis Biotherapeutics-4.29% -10.26% -4.30%
Aerovate Therapeutics N/A -90.19%-77.47%

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 5 mentions for Arcutis Biotherapeutics and 1 mentions for Aerovate Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.00 beat Aerovate Therapeutics' score of 0.75 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcutis Biotherapeutics
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aerovate Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Arcutis Biotherapeutics presently has a consensus target price of $34.00, indicating a potential upside of 45.18%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Arcutis Biotherapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcutis Biotherapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Arcutis Biotherapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Summary

Arcutis Biotherapeutics beats Aerovate Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Aerovate Therapeutics compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aerovate Therapeutics has lower revenue, but higher earnings than MorphoSys. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$238.28M11.99-$205.35M-$3.48N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

In the previous week, Aerovate Therapeutics had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for Aerovate Therapeutics and 0 mentions for MorphoSys. Aerovate Therapeutics' average media sentiment score of 0.75 beat MorphoSys' score of 0.00 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
MorphoSys Neutral
Aerovate Therapeutics Positive

Aerovate Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Aerovate Therapeutics' return on equity of -90.19% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
MorphoSys-226.79% -694.31% -22.55%
Aerovate Therapeutics N/A -90.19%-77.47%

Summary

Aerovate Therapeutics beats MorphoSys on 7 of the 12 factors compared between the two stocks.

Get Aerovate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVTE vs. The Competition

Export
MetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$710.71M$892.88M$6.25B$11.87B
Dividend YieldN/A4.84%2.73%5.21%
P/E Ratio-8.201.7229.0428.47
Price / SalesN/A120.50476.6160.94
Price / CashN/A20.0727.6236.52
Price / Book6.197.609.676.67
Net Income-$75.52M-$4.80M$3.55B$332.53M
7 Day Performance-8.68%-0.02%1.70%2.01%
1 Month Performance58.30%5.52%5.62%9.20%
1 Year Performance96.47%30.99%34.42%39.59%

Aerovate Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVTE
Aerovate Therapeutics
N/A$24.52
+1.2%		N/AN/A$710.71MN/AN/A20
BEAM
Beam Therapeutics
2.8931 of 5 stars		$30.56
+4.8%		$49.36
+61.5%		N/A$3.00B$139.74MN/A510
GMTX
Gemini Therapeutics
N/A$68.85
flat		N/AN/A$2.98BN/AN/A30
DYN
Dyne Therapeutics
3.4525 of 5 stars		$18.16
+0.7%		$35.14
+93.5%		N/A$2.98BN/AN/A100
ARQT
Arcutis Biotherapeutics
3.3955 of 5 stars		$23.29
-0.6%		$34.00
+46.0%		N/A$2.93B$376.07MN/A150

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AVTE) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
You’re Being LIED To About The Iran War
The mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey ...
Banyan Hill Publishing | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel